Anionic 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) liposomes induce antigen-specific regulatory T cells and prevent atherosclerosis in mice

Benne, Naomi; Duijn, Janine van; Vigario, Fernando Lozano; Leboux, Romain; Veelen, Peter A. van; Kuiper, Johan; Jiskoot, Wim; Slütter, Bram

doi:10.1016/j.jconrel.2018.10.028

Cited by 55 publications

(54 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with our findings, Slütter and coworkers demonstrated that PG‐containing liposomes mediated an increased antigen‐specific immune cell response with respect to PS‐containing liposomes. [ 66 ] Moreover, PS‐liposomes are mainly dependent on the SR, whereas PG‐liposomes have at least one additional mechanism of uptake such as a Toll‐like receptor 4 (TLR4)‐dependent binding. [ 67 ] Another explanation for the higher potency of PG‐liposomes could be attributed to their increased affinity to the complement component 1q (C1q) compared with PS‐liposomes.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Beyond Trial and Error: A Systematic Development of Liposomes Targeting Primary Macrophages

Weber

Ivan

Proulx

et al. 2021

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Monocytes/macrophages are phagocytic innate immune cells playing a pivotal role in tissue homeostasis, inflammation, and antitumor immunity in a microenvironment‐dependent manner. By expressing pattern recognition and scavenger receptors on their surface, macrophages selectively take up pathogens, cellular debris, and often—undesirably—drug delivery systems. On the other hand, the propensity of phagocytic cells to internalize particulate drug carriers is used to load them with a cargo of choice, turning the monocytes/macrophages into a diagnostic or therapeutic Trojan horse. Identifying the ideal physicochemical properties of particulate carriers such as liposomes to achieve the most efficient macrophage‐mediated drug delivery has been object of extensive research in the past, but the studies reported so far rely solely on trial‐and‐error approaches. Herein, a design of experiment (DoE) strategy to identify the optimal liposomal formulation is proposed, fully characterized in terms of size, surface charge, and membrane fluidity, to maximize macrophage targeting. The findings are validated using mouse bone marrow‐derived macrophages, a primary preparation modeling in vivo monocyte‐derived macrophages, thus confirming the robustness and versatility of the systematic and iterative approach and suggesting the promising potential of the DoE approach for the design of cell‐targeting delivery systems.

show abstract

Section: Resultsmentioning

confidence: 99%

“…It was found that PG liposomes attract complement proteins, especially C1q, from the circulation more efficiently than PS liposomes. [ 66 ] However, further investigations are needed to elucidate the specific receptor involved in the uptake and its mechanism.…”

Section: Resultsmentioning

confidence: 99%

Beyond Trial and Error: A Systematic Development of Liposomes Targeting Primary Macrophages

Weber

Ivan

Proulx

et al. 2021

Advanced NanoBiomed Research

View full text Add to dashboard Cite

show abstract

“…In a study by Benne et al, 10 nmol of this vaccine was shown to decrease plaque formation by 50% and reduce serum cholesterol concentrations in LDLR -/-mice. Importantly, administration of the vaccine resulted in increased antigen-specific CD4+ T cell proliferation after 7 days [105]. Peptide plaque-specific antigens The peptides ovalbumin-derived CD4 + Tcell-specific peptide (OVA323) and proprotein convertase subtilisin/kexin type 9 (PCSK9) are plaque-specific antigens that have also been incorporated into liposomes.…”

Section: Liposomes As Vaccinesmentioning

confidence: 99%

“…The positive charge on these liposomes facilitates electrostatic interaction with negatively charged proteoglycans on the cell membrane. Therefore, delivery of a gene to the cell is enhanced [105,119].…”

Section: Liposomes As Nonviral Gene Delivery Vectorsmentioning

confidence: 99%

A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

Kiaie

Gorabi

Penson

et al. 2020

Drug Discovery Today

View full text Add to dashboard Cite

Highlights  Atherosclerotic cardiovascular disease (ASCVD) is a major cause of mortality and morbidity worldwide.  Improved visualization of early atherosclerosis and better management of residual risk can reduce ASCVD burden.  Recent research has investigated the potential of biomaterials and nanomedicines in meeting this demand.  Liposomes have a wide range of applications in both imaging and treatment of atherosclerosis.  We review the scientific and clinical evidence relating to the use of liposomes in the context of ASCVD. Teaser: This review describes the experimental and clinical evidence for the use of liposomes in the diagnosis and management of atherosclerotic cardiovascular disease. The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD.

show abstract

“…Atherosclerosis (AS) is a chronic inflammatory disease as the dominant pathology of diverse cardiovascular diseases and is manifested with oxidized low‐density lipoprotein and (ox‐LDL) accumulated in the intima of arteries (Benne et al, ). It occurs mainly at blocked blood flow regions, and medium‐sized artery inner membrane, especially the bifurcations and arterial branch (Moore & Tabas, ; Tabas, Garcia‐Cardena, & Owens, ).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of microRNA‐103 attenuates inflammation and endoplasmic reticulum stress in atherosclerosis through disrupting the PTEN‐mediated MAPK signaling

Jiang

Qiao

Wang

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Atherosclerosis (AS), a chronic disorder of large arteries, is the underlying pathological process of heart disease and stroke. Former researchers have found that microRNAs (miRs) are involved in the several key processes of AS. Apolipoprotein E knockout (ApoE −/− ) mice fed a high-fat-diet (HFD) to establish AS model. The expression of miR-103 was characterized in the mice model. The effects of miR-103 on inflammation and endoplasmic reticulum stress (ERS) were analyzed when the expression of miR-103 was inhibited in ApoE −/− mice fed an HFD and human aortic endothelial cells (HAECs) exposed to oxidized low-density lipoprotein (ox-LDL). The relationship between miR-103 and phosphatase and tensin homolog (PTEN) was identified by luciferase activity detection and real-time quantitative polymerase chain reaction (RT-qPCR). Gain-and loss-function approaches were further applied for investigating the regulatory effects of miR-103 and PTEN on ERS. Role of MAPK signaling was then analyzed using PD98059 to block this pathway. miR-103 was highly expressed in the ApoEApoE −/− mice fed an HFD. Downregulation of miR-103 suppressed inflammation and ERS in endothelial cells isolated from ApoE −/− mice fed a HFD and ox-LDL-exposed HAECs. In addition, miR-103 can target PTEN and downregulate its expression. Overexpression of PTEN reversed the miR-103-induced activation of MAPK signaling. Moreover, PTEN upregulation or MAPK signaling inhibition ease miR-103-induced inflammation and ERS in vivo and in vitro. Thus, miR-103 depletion restrains the progression of AS through blocking PTEN-mediated MAPK signaling.

show abstract

Anionic 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) liposomes induce antigen-specific regulatory T cells and prevent atherosclerosis in mice

Cited by 55 publications

References 88 publications

Beyond Trial and Error: A Systematic Development of Liposomes Targeting Primary Macrophages

Beyond Trial and Error: A Systematic Development of Liposomes Targeting Primary Macrophages

A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

Inhibition of microRNA‐103 attenuates inflammation and endoplasmic reticulum stress in atherosclerosis through disrupting the PTEN‐mediated MAPK signaling

Contact Info

Product

Resources

About